Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GRCL

Gracell Biotechnologies Inc ADR

Dec 01 • 04:00PM ET

5.29

Dollar change +0.42
Percentage change 8.62	%

Healthcare • Biotechnology • China • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.02	Insider Own	25.65%	Shs Outstand	95.93M	Perf Week	4.75%
Market Cap	507.47M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	0.00%	Shs Float	71.32M	Perf Month	42.97%
Income	-70.80M	PEG	-	EPS next Q	-0.04	Inst Own	33.21%	Short Float / Ratio	1.29% / 1.87	Perf Quarter	50.28%
Sales	0.00M	P/S	-	EPS this Y	17.55%	Inst Trans	-3.47%	Short Interest	0.92M	Perf Half Y	72.88%
Book/sh	2.31	P/B	2.29	EPS next Y	6.45%	ROA	-27.34%	Target Price	11.71	Perf Year	62.77%
Cash/sh	2.44	P/C	2.17	EPS next 5Y	-	ROE	-32.38%	52W Range	1.40 - 6.99	Perf YTD	130.00%
Dividend	-	P/FCF	-	EPS past 5Y	-68.83%	ROI	-31.22%	52W High	-24.32%	Beta	-0.78
Dividend %	-	Quick Ratio	7.73	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	277.86%	ATR	0.50
Employees	314	Current Ratio	7.73	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	64.66	Volatility	16.84% 12.18%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	70.00%	Profit Margin	-	Rel Volume	0.52	Prev Close	4.87
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 13 BMO	Payout	-	Avg Volume	494.36K	Price	5.29
Recom	1.00	SMA20	14.35%	SMA50	47.76%	SMA200	68.98%	Volume	257,122	Change	8.62%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-23	Initiated	Evercore ISI	Outperform
Oct-19-23	Initiated	Stifel	Buy	$11
Mar-27-23	Resumed	Wells Fargo	Overweight	$7
Dec-08-22	Initiated	H.C. Wainwright	Buy	$6
Sep-22-22	Initiated	Citigroup	Buy	$12
Aug-18-22	Resumed	Wells Fargo	Overweight
Jun-01-22	Initiated	Cantor Fitzgerald	Overweight	$20
Apr-04-22	Initiated	BTIG Research	Buy	$18
Feb-03-21	Initiated	Citigroup	Buy	$35
Feb-02-21	Initiated	Wells Fargo	Overweight	$33
Feb-02-21	Initiated	Piper Sandler	Overweight	$40
Feb-02-21	Initiated	Jefferies	Buy	$30

Show Previous Ratings

Nov-27-23 08:00AM	Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus (GlobeNewswire) +6.93%
Nov-23-23 12:00PM	What Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect? (Zacks)
Nov-16-23 08:00AM	Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit (GlobeNewswire)
Nov-14-23 01:03AM	Q3 2023 Gracell Biotechnologies Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Loading…
Nov-13-23 07:30AM	Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-23 08:36AM	Should You Buy Gracell Biotechnologies (GRCL) Ahead of Earnings? (Zacks)
Nov-08-23 08:30AM	Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program (GlobeNewswire) +6.02%
Nov-02-23 09:00AM	Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65 American Society of Hematology Annual Meeting & Exposition (GlobeNewswire) +8.65%
Nov-01-23 04:00PM	Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences (GlobeNewswire) +10.12%
Oct-31-23 09:00AM	Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey)
09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
08:30AM	Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023 (GlobeNewswire)
Sep-27-23 08:30AM	Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate (GlobeNewswire)
04:00PM	Loading…
Sep-26-23 04:00PM	Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Sep-19-23 09:21AM	Gracell Biotechnologies CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders (GlobeNewswire)
Sep-14-23 09:15AM	Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-12-23 09:55AM	Gracell Biotechnologies Inc. Sponsored ADR (GRCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) -6.06%
Sep-06-23 08:00AM	Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting (PR Newswire)
Aug-24-23 04:10PM	Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 09:02PM	RA Capital Management, L.P. Acquires Significant Stake in Gracell Biotechnologies Inc. (GuruFocus.com)
Aug-15-23 12:51AM	Q2 2023 Gracell Biotechnologies Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:15AM	Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-23 02:12PM	Why Shares of Gracell Biotechnologies Are Rising Monday (Motley Fool) +11.99%
07:45AM	Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors (PR Newswire)
Jul-31-23 04:02PM	Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023 (GlobeNewswire) -5.75%
09:00AM	Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-20-23 08:30AM	Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium (GlobeNewswire)
Jun-14-23 11:45AM	Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why (Zacks) -5.60%
03:29PM	Loading…
Jun-13-23 03:29PM	Why Shares of Gracell Biotechnologies Jumped Tuesday (Motley Fool) +28.06%
Jun-10-23 10:30AM	Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkins Lymphoma at EHA2023, Highlighting 100% Overall Response Rate (GlobeNewswire)
Jun-03-23 02:15PM	Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting (PR Newswire)
May-24-23 04:01PM	Gracell Biotechnologies to Participate in Jefferies Healthcare Conference (GlobeNewswire) +10.53%
May-16-23 12:12AM	Q1 2023 Gracell Biotechnologies Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 09:15AM	Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd (GlobeNewswire) +9.31%
07:00AM	Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update (GlobeNewswire)
07:00AM	Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) (PR Newswire)
May-11-23 04:00PM	Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress (PR Newswire)
May-10-23 04:19PM	Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-02-23 04:00PM	Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023 (GlobeNewswire)
Apr-26-23 10:15AM	Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting (PR Newswire)
Apr-25-23 04:13PM	Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022 (GlobeNewswire) -16.91%
Mar-22-23 04:10PM	Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-14-23 12:27AM	Q4 2022 Gracell Biotechnologies Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-23 07:30AM	Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update (GlobeNewswire)
Feb-28-23 08:00AM	Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Feb-27-23 08:00AM	Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023 (PR Newswire)
Feb-26-23 09:10AM	Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares Could Be 39% Below Their Intrinsic Value Estimate (Simply Wall St.)
Feb-14-23 08:46AM	Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +6.28%
Feb-13-23 07:30AM	Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma (PR Newswire)
Feb-03-23 07:30AM	Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma (PR Newswire)
Jan-16-23 06:23AM	Gracell Biotechnologies Inc.'s (NASDAQ:GRCL) largest shareholders are private equity firms with 34% ownership, insiders own 27% (Simply Wall St.)
Dec-12-22 10:39AM	Gracell Biotech's Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates (Benzinga)
Dec-10-22 06:15PM	Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate (PR Newswire)
Dec-08-22 01:28PM	Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims (Benzinga) +8.75%
Nov-23-22 08:00AM	Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences (PR Newswire)
Nov-16-22 08:00AM	Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award (PR Newswire)
Nov-14-22 07:15AM	Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 09:10AM	Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition (PR Newswire) +10.64%
Oct-31-22 09:00AM	Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 (PR Newswire)
Oct-24-22 09:00AM	Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences (PR Newswire) -15.79%
Oct-17-22 08:05AM	Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia (PR Newswire) +13.95%
Sep-14-22 08:30AM	Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences (PR Newswire)
Aug-29-22 09:00AM	Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences (PR Newswire) -11.11%
Aug-15-22 07:15AM	Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-22 09:46AM	Do Institutions Own Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares? (Simply Wall St.) -6.33%
Aug-02-22 09:00AM	Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022 (PR Newswire) +7.85%
Aug-01-22 08:00AM	Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer (PR Newswire) -6.23%
Jul-26-22 08:30AM	Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference (PR Newswire)
Jul-19-22 08:00AM	Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer (PR Newswire)
Jun-14-22 08:00AM	Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences (PR Newswire) +9.26%
Jun-13-22 10:12AM	Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients (Benzinga)
Jun-12-22 08:00AM	Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients (PR Newswire)
Jun-03-22 11:00AM	Gracell Biotechnologies Schedules Clinical Update Call After EHA2022 (PR Newswire)
May-26-22 05:01PM	Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting (PR Newswire)
May-19-22 08:30AM	Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences (PR Newswire) +7.96%
May-16-22 07:30AM	Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire)
May-12-22 10:01AM	Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress (PR Newswire) +13.77%
May-04-22 08:30AM	Gracell Biotechnologies to Participate in Three Investor Conferences in May (GlobeNewswire)
May-02-22 08:00AM	Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022 (GlobeNewswire) +10.22%
Apr-28-22 10:30AM	Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting (PR Newswire)
Apr-22-22 05:00PM	Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021 (GlobeNewswire)
Apr-14-22 08:30AM	Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting (PR Newswire) -5.50%
Apr-08-22 04:00PM	Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL (PR Newswire) +5.99%
Mar-29-22 08:30AM	Gracell Biotechnologies to Participate in Three Investor Conferences in April (GlobeNewswire)
Mar-14-22 07:30AM	Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire) -28.24%
Mar-10-22 04:30PM	Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-08-22 04:30PM	Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 (PR Newswire)
Mar-02-22 08:00AM	Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022 (GlobeNewswire)
Mar-01-22 09:03AM	What Type Of Shareholders Own The Most Number of Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares? (Simply Wall St.)
Feb-22-22 07:30AM	Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform (PR Newswire)
Feb-17-22 08:30AM	Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma (PR Newswire) -5.32%
Feb-03-22 08:00AM	Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit (GlobeNewswire)
Jan-18-22 08:00AM	Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference (GlobeNewswire)
Jan-12-22 08:00AM	Gracell Biotechnologies Unveils Innovation Center in U.S. (PR Newswire)
Dec-25-21 02:38AM	Federated Hermes Prudent Bear Fund Buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, ... (GuruFocus.com)
Dec-16-21 08:00AM	Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index (PR Newswire)
Nov-23-21 09:00AM	Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan (PR Newswire) +22.10%
Nov-19-21 07:07AM	20 Stocks Moving in Friday's Pre-Market Session (Benzinga)

Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of discovering and developing cell therapies to resolve industry challenges and fulfill unmet medical needs in the treatment of cancer. The company was founded by Wei Cao in May 2017 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRCL

Gracell Biotechnologies Inc ADR

Upgrade your FINVIZ experience